EZLIFE BIO
Company Snapshot
Company Overview
Ezlife Bio Inc. is developing and commercializing its platform, EFIRM, for cancer-based liquid biopsy applications, among others. EFIRM (electric field-induced release and measurement method) employs a conducting polymer-based electrochemical chip and array of electrodes. An electrical field releases and detects specific mutations in biofluids.
The company is working with the University of California, Los Angeles (UCLA), to develop a liquid biopsy assay for the early detection of lung cancer. In October 2018, this team received a $5 million grant from the National Cancer Institute (NCI) to develop and validate the assay for lung cancer. The assay assesses 10 DNA mutations involved in lung cancers and has a complementary six-biomarker panel of microRNAs. A key goal of the project is to identify those lung cancer biomarkers in patients with indeterminate lung nodules and where the patient may or may not have lung cancer.
Company's Business Segments
- Product : EFIRM96 Detection Device, Others
- Services : Panel Design, Reagent Formulation, Customizable Report, Others
Applications/End User Industries
- Biotechnology
- Pharmaceuticals
- Healthcare
- Bioinformatics
- Agriculture
